Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.
By A. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, W. Fleig. Journal of Clinical Oncology, 2006
1,171 citations recorded by the source corpus.
Subfields: Gastroenterology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/a548a0cbb3e055c39ebdf86cab72cfc2c2900bd3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. (2008, background): “Although a large number of chemotherapy regimens have been tested in randomized studies, there is no internationally accepted standard of care, and uncertainty remains regarding the choice of the chemotherapy regimen [7].”
- An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer (2016, background): “…for a number of cancers have demonstrated efficacy gains of combination chemotherapy regimens over single-agent treatments (Delbaldo et al. 2004, Wagner 2006), and in this work we found that 80% of all chemotherapy clinical trials for advanced gastric cancer have tested multidrug treatments.”
- Targeting Metabolism for Cancer Therapy (2017, background): “5-FU and the related 5-FU-prodrug capecitabine remain widely used chemotherapies today and are an important treatment for gastrointestinal cancers (Heidelberger et al., 1957; Wagner et al., 2006).”